Dr. Jean-Pierre (“JP”) Bizzari currently is a member of the Board of Directors of Halozyme, Nordic Nanovector Onexeo, Transgene, and previously of Celator Pharmaceuticals (acquired by Jazz Pharmaceuticals). JP has been involved in the clinical development of several anticancer agents such as Taxotere®, Eloxatin®, Abraxane®, Irinotecan® (CPT-11). As a world-renowned oncology expert, he is a member of the Scientific Advisory Board of the French National Cancer Institute (INCa) and European Organization of Research and Treatment of Cancer (EORTC) and Chairman of the New Drug Advisory Committee. Prior to serving as an advisor to emerging biotechnology companies, JP served as EVP and Group Head of Clinical Oncology Development (U.S., Europe, and Asia/Japan) at Celgene (2008-2015). Previously, JP served as VP of Clinical Oncology Development at Sanofi-Aventis (2002-2008), VP of Clinical Oncology at joined Rhône-Poulenc Rorer (1993-2002), and Head of Oncology at Servier (1983-1993). He holds an M.D. specialized in oncology from the University of Nice (France) and has trained successively at the Pitié-Salpêtrière hospital in Paris, at Ontario Cancer Institute, and Montreal McGill Cancer Center in Canada.
Dr. Scott Dax is a Senior Advisor to Context focusing on medicinal chemistry. In addition to his role at Context, Scott is a Co-founder of CerSci Therapeutics and is a Project Manager at BioMotiv, an early stage venture capital fund. Previously, Scott served as Chief Technology Officer at Galleon Pharmaceuticals, a venture-backed startup focused on developing therapeutics to treat narcotic-induced respiratory depression and sleep apnea. Prior, Scott served as Analgesics Research Team Leader at Johnson & Johnson where he gained extensive experience in the Sigma1 field. Earlier in his career, Scott held positions of increasing responsibility at DuPont-Merck and Hoffmann-LaRoche. Scott is an inventor of over 100 issued patents and 100 publications and presentations in peer-reviewed journal and professional societies. He holds an M.S. and Ph.D. in Chemistry from the University of Michigan and completed his postdoctoral training at the University of Wisconsin.
Dr. Felix Kim is the Co-founder, Chief Scientific Officer, and Chair of Scientific Advisory Board of Context Therapeutics. In addition, Felix is currently an Assistant Professor in the Department of Pharmacology & Physiology at Drexel University College of Medicine and is Secretary/Treasurer of the Translational and Clinical Pharmacology division of the American Society for Pharmacology and Experimental Therapeutics (ASPET). Prior to receiving his faculty position at Drexel, Felix completed a Post-Doctoral Fellowship with Dr. Gavril Pasternak at the Memorial Sloan Kettering Cancer Center. Felix is a leading authority on Sigma1 biology, having authored some of the seminal works in the field. He holds a Ph.D. in Biochemistry from Universitè Montepellier (France) and a B.S. in Biology from University of California San Diego.
Dr. Kantoff is the Chairman of the Department of Medicine at Memorial Sloan Kettering Cancer Center in New York, which is the leading development and testing center for novel cancer therapies. He also served as Director of The Lank Center for Genitourinary Oncology, Chief of the Division of Solid Tumor Oncology, Vice Chair of the Department of Medical Oncology, and Chair of the Executive Committee on Clinical Research at the Dana-Farber Cancer Institute. He is a Professor Emeritus of Medicine at Harvard Medical School, the Chairman of the Global Treatment Science Network of the Prostate Cancer Foundation, and member of numerous professional societies and editorial boards. Dr. Kantoff published more than 350 research articles on a variety of topics, written nearly 100 reviews and monographs on cancer and has edited numerous books, including Prostate Cancer, A Multi-Disciplinary Guide published by Blackwell, and Prostate Cancer: Principles and Practice, a definitive text on prostate cancer.
Dr. Knudsen is the Director of the Sidney Kimmel Cancer Center at Thomas Jefferson University. Karen serves on a multitude of national scientific advisory boards and committees, including those for the National Institutes of Health (NIH), American Association for Cancer Research, the Endocrine Society, and the Prostate Cancer Foundation. She is the Editor-in-Chief of Molecular Cancer Research, a senior editor for Cancer Research, and is on the editorial boards of Molecular Cancer Therapeutics, Endocrine-Related Cancer, American Journal of Pathology, Molecular Endocrinology, and Oncogene. Karen has received numerous awards for her research, including the Ronald Ross Award for Excellence in hormone-dependent malignancies from the Pacific Rim Breast and Prostate Cancer Research Organization and the Richard E. Weitzman Laureate Award from the Endocrine Society. Karen’s research identifying tumor suppressor and hormone receptor alterations have uncovered new targets for treating advanced disease, and led to the development of several innovative biomarker-driven clinical trials. Karen received a BS in Biology from The George Washington University, a PhD in Molecular Biology from the University of California at San Diego, and performed a post-doctoral fellowship at the Ludwig Institute for Cancer Research.
Dr. Kruse is Assistant Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. In 2016, Andrew’s group published in Nature the first crystal structure of Sigma1. His research focuses on the molecular basis of transmembrane signaling through pharmacology and structural biology. This work was recently described as a “landmark achievement for molecular pharmacology and drug discovery” (F1000Prime review by Bryan Roth, UNC Chapel Hill). Andrew has received multiple prestigious awards, including the Sloan Research Fellowship (2017), Forbes 30 under 30 (2016), and the NIH Director’s Early Independence Award (2015). He holds bachelor’s degrees in Biochemistry and Mathematics from the University of Minnesota and a PhD in Structural Biology from Stanford University.
Dr. Montgomery is Professor of Medicine, University of Washington School of Medicine, is Clinical Director of Genitourinary Medical Oncology at the Seattle Cancer Care Alliance, and is a GU oncologist with the Veterans Affairs Puget Sound Health Care System. Bruce has lead numerous genitourinary cancer clinical trials and specializes in the treatment of high risk and advanced prostate cancer and drug resistance to hormonal therapy and taxane chemotherapy. He holds an MD from Duke University School of Medicine, and he performed his residency at Brigham and Women’s Hospital and an oncology fellowship at the University of Washington School of Medicine.
Dr. Mostaghel is Associate Member of the Clinical Research Division at Fred Hutchinson Cancer Research Center and Associate Professor of Medical Oncology Division at the University of Washington School of Medicine. Elahe is a genitourinary oncologist who has lead multiple translational research programs on the development of strategies to treat hormone refractory prostate cancer and is involved in clinical trials for all phases of prostate cancer therapy. She is a program leader in the Pacific Northwest Prostate Cancer Specialized Programs of Research Excellence (SPORE). She holds AB in Biology from Harvard University, a PhD in immunology and MD from Duke University, and performed her residency at the University of California at San Francisco and an oncology fellowship at the Fred Hutchinson Cancer Research Center.